Bhattacharyya S N, Ghoshal J, Sharma S K, Halstead N, John B, Launer M A, Mukherjee P K, Zigmond A S
Pharmatherapeutica. 1987;5(1):1-8.
An assessment of the efficacy and tolerability of zuclopenthixol dihydrochloride tablets in the treatment of acute psychotic episodes was undertaken in 63 patients in an open multi-centre study. Most patients prior to entering the study had received other neuroleptic drugs, but with inadequate effect. During the 10-week study, the dosage of zuclopenthixol dihydrochloride tablets could be adjusted to obtain optimum clinical benefit. The majority of patients received 20 to 75 mg daily (range 10 to 150 mg daily) at the start of the study and later, for most of those patients successfully treated, the dosage was 20 to 55 mg daily. Assessments before and during treatment utilized the BPRS and CGI rating scales and a check-list of side-effects. A successful response to treatment was achieved in 70% of 50 patients with schizophrenia or schizophreniform psychoses and in 69% of 13 patients with mania or hypomania. Almost half (30) of the patients studied had a successful response within 4 weeks of starting treatment and some after only 1 week of treatment. All patients but 1 had either no side-effects or side-effects not overtly affecting performance.
在一项开放性多中心研究中，对63例患者进行了二盐酸珠氯噻醇片治疗急性精神病性发作的疗效和耐受性评估。大多数患者在进入研究之前曾接受过其他抗精神病药物治疗，但效果不佳。在为期10周的研究期间，可调整二盐酸珠氯噻醇片的剂量以获得最佳临床效益。大多数患者在研究开始时每日服用20至75毫克（每日范围为10至150毫克），后来，对于大多数成功治疗的患者，剂量为每日20至55毫克。治疗前和治疗期间的评估采用BPRS和CGI评定量表以及一份副作用清单。50例精神分裂症或精神分裂症样精神病患者中有70%对治疗有成功反应，13例躁狂或轻躁狂患者中有69%对治疗有成功反应。几乎一半（30例）研究患者在开始治疗后4周内有成功反应，有些患者仅在治疗1周后就有反应。除1例患者外，所有患者均无副作用或副作用未明显影响其表现。
